<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209780</url>
  </required_header>
  <id_info>
    <org_study_id>V71_18</org_study_id>
    <nct_id>NCT01209780</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age</brief_title>
  <official_title>A Multi-center, Phase III, Randomized, Observer Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Trivalent Subunit Inactivated Flu Vaccine in Healthy Children and Adolescents 3 to 17 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and immunogenicity in healthy children and adolescents
      after one or two IM dose(s) of trivalent subunit inactivated flu vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Antibody Responses of Investigational TIV to Control Vaccine in Terms of the Percentage of Subjects Achieving Seroconversion</measure>
    <time_frame>Day 22 for non-naive/Day 50 for naive subjects</time_frame>
    <description>The non-inferiority of the antibody responses of investigational TIV compared to control TIV assessed in terms of the percentage of subjects achieving seroconversion, against the three homologous vaccine strains,in children 3 to 8 years of age, at 21 days after last vaccination.
Seroconversion was defined as a pre-vaccination haemagglutinin inhibition (HI) titer &lt;1:10 and post-vaccination HI titer ≥1:40 or as a pre-vaccination HI titer ≥1:10 and at minimum four-fold rise in post-vaccination antibody titer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Antibody Responses of Investigational TIV to Control Vaccine in Terms of Post Vaccination Geometric Mean Titers (GMTs)</measure>
    <time_frame>Day 22 for non-naive/Day 50 for naive subjects</time_frame>
    <description>The non-inferiority of the antibody responses of investigational TIV compared to control vaccine assessed in terms of post vaccination GMTs, at 21 days after last vaccination against the three homologous vaccine strains in 3 to 8 year old children.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Achieving HI Titers ≥40 Following Vaccination With Investigational TIV or Control Vaccine.</measure>
    <time_frame>Day 22 for non-naive/Day 50 for naive subjects</time_frame>
    <description>The percentages of 3 to 8 year old subjects achieving HI titers ≥40 after receiving either one or two doses of investigational TIV or control vaccine, 21 days after last vaccination, are reported.
This criterion according to the US (CBER)guideline is met if the lower bound of the two sided 95%CI for percentage of subjects achieving HI titers ≥40, is ≥70%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Seroconversion in Antibody Titers Following Vaccination With Investigational TIV or Control Vaccine</measure>
    <time_frame>Day 22 for non-naive/Day 50 for naive</time_frame>
    <description>The percentages of 3 to 8 years-old subjects achieving seroconversion in HI antibody titers after receiving either one or two doses of investigational TIV or control vaccine, at 21 days after last vaccination, are reported.
This criterion, according to the US (CBER) guideline, is met if the lower limit of 95% CI of percentage of subjects achieving seroconversion or significant increase at day 22 and day 50 (21 days after last vaccination) is ≥40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Vaccine-naive Children Achieving HI Titers ≥40 After Receiving Two Doses of Investigational TIV or Control Vaccine.</measure>
    <time_frame>Day 1, Day 29, and Day 50</time_frame>
    <description>The percentage of 3 to 8 years-old vaccine-naive subjects achieving HI titers ≥40, after receiving two doses of investigational TIV or control vaccine. The time frame of evaluation was 28 days after first (Day 29) and 21 days after second vaccine dose (Day 50).
This criterion according to the US (CBER) guideline is met if the lower bound of the two sided 95%CI for percentage of subjects achieving HI titers ≥40 is ≥70%, for each vaccine strain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Vaccine-naive Children Achieving Seroconversion in Antibody Titers, After Receiving Two Doses of Investigational TIV or Control Vaccine</measure>
    <time_frame>Day 29 and Day 50</time_frame>
    <description>The percentages of 3 to 8 years-old vaccine naive children achieving seroconversion or significant increase in HI antibody titers after receiving two doses of investigational TIV or control vaccine, are reported. The time frame of evaluation was 28 days after first (Day 29) and 21 days after the second dose (Day 50).
This criterion, according to the US (CBER) guideline, is met if the lower limit of 95% CI of percentage of subjects achieving seroconversion or significant increase at day 29 and day 50 is ≥40, for each vaccine strain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Adverse Events After Vaccination With Investigational TIV and Control Vaccine</measure>
    <time_frame>Day 1 to 7 after vaccination</time_frame>
    <description>The number of 3-17 year old children with solicited local and systemic adverse events and other adverse events, after receiving either one or two doses of investigational TIV as compared to control vaccine are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events After Vaccination With Investigational TIV and Control Vaccine</measure>
    <time_frame>Day 1 to 180 (non-naive )/Day 1 to 209 (naive)</time_frame>
    <description>The number of 3-17 year old children reporting any unsolicited adverse event and any serious adverse event (SAE) after receiving either one or two doses of investigational TIV and control vaccine are reported.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3116</enrollment>
  <condition>Seasonal Influenza</condition>
  <arm_group>
    <arm_group_label>TIV (3-8 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-Naive subjects received one dose and naive subjects received two doses, administered 4 weeks apart, of investigational trivalent influenza vaccine (TIV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control TIV (3-8 years)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-Naive subjects received one dose and Naive subjects received two doses, administered 4 weeks apart, of control vaccine. Subjects aged 3 to &lt;4 years and subjects aged 4 to 8 years received different control TIV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV ( 9-17 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects received one dose of investigational TIV. The subjects in this cohort were included only for safety analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control TIV ( (9-17 years)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects received one dose of the control vaccine. The subjects from this cohort were included only for safety analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TIV</intervention_name>
    <description>Investigational egg-derived trivalent subunit influenza vaccine.</description>
    <arm_group_label>TIV (3-8 years)</arm_group_label>
    <arm_group_label>TIV ( 9-17 years)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TIVf</intervention_name>
    <description>US licensed trivalent inactivated subunit influenza vaccine -Fluvirin (Novartis Vaccines and Diagnostics) is approved for use in subjects ≥4 years.</description>
    <arm_group_label>Control TIV (3-8 years)</arm_group_label>
    <arm_group_label>Control TIV ( (9-17 years)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator TIV</intervention_name>
    <description>US licensed trivalent subunit inactivated influenza vaccine- Fluzone (Sanofi Pasteur) is approved for use in children &lt;4 years.</description>
    <arm_group_label>Control TIV (3-8 years)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 3 to 17 years, in good health as determined by medical history,
             physical examination and clinical judgment of the investigator

          -  Documented consent provided by parents or legal guardians

          -  For individuals 8 years of age and older, informed assent to participate in the study
             after the nature of the study had been explained to them in terms they could
             understand

          -  Individuals and parents/guardians who were able to comply with all study procedures
             and were available for all clinic visits scheduled in the study

        Exclusion Criteria:

          -  Parents or legal guardians and individuals who are not able to comprehend and to
             follow all required study procedures for the whole period of the study

          -  Parents or legal guardians and individuals providing assent who do not consent to the
             retention of the subject's serum samples after study completion

          -  Individuals with behavioral or cognitive impairment or psychiatric disease that, in
             the opinion of the investigator, may have interfered with the subject's ability to
             participate in the study

          -  Individuals with history or any illness that, in the opinion of the investigator,
             might have interfered with the results of the study or posed additional risk to the
             subjects due to participation in the study

          -  History of any anaphylaxis, serious vaccine reactions, or hypersensitivity to
             influenza viral proteins, latex, to any excipients, and to eggs (including ovalbumin),
             chicken protein, influenza viral protein, kanamycin, neomycin sulphate,
             cetyltrimethylammonium bromide (CTAB), polysorbate 80, neomycin, polymixin,
             formaldehyde, thimerosal, beta propiolactone, or nonoxynol-9

          -  History of any serious disease, such as:

               1. cancer

               2. history of serious chronic, rheumatologic, neurologic and hematologic diseases

               3. history of underlying medical condition such as inborn errors of metabolism

          -  Known or suspected impairment/alteration of immune function, including:

               1. chronic use of oral steroids within 60 days prior to Visit 1 (use of inhaled,
                  intranasal, or topical corticosteroids is allowed)

               2. receipt of immunostimulants within 60 days prior to Visit 1

               3. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma
                  derivates within 3 months prior to Visit 1 or planned during the full length of
                  the study

               4. HIV infection or HIV-related disease

          -  Pregnant or breast-feeding female and any positive or indeterminate pregnancy test

          -  Received an influenza vaccine within 6 months prior to Visit 1

          -  Laboratory-confirmed or suspected influenza disease within 6 months prior to Visit 1

          -  Receipt of another vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for
             live vaccines) prior to enrollment in this study

          -  Experienced a fever and/or any acute illness within 3 days prior to each study
             vaccination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centro de Atención e Investigación Medica - CAIMED</name>
      <address>
        <city>Carrera 42A # 17-50, Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical research institute ,S.C(CRI), Blvd Manuel Avila Camacho 1994 Consultorio 1103 Col. San Lucas Tepetlacalco, C.P.54055 Tlalnepantla</name>
      <address>
        <city>Estado de México</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Magally Ruiz, Street Bolivar</name>
      <address>
        <city>Panama - La Chorrera</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Hospital San Fernando, Floor 4 Office 419 via España las Sabanas</name>
      <address>
        <city>Panamá</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorios America Floor 2 Office 201-1, Via España Vista Hermosa</name>
      <address>
        <city>Panamá</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorios Medicos San Judas Tadeo Principal Street, Floor 5 Office 507, Villa Lucre</name>
      <address>
        <city>Panamá</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Taft Avenue, Manila</city>
        <state>Manila</state>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine, Department of Health Compound</name>
      <address>
        <city>FILINVEST Corporate City, Alabang</city>
        <state>Muntinlupa City</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine, Department of Health Compound, FILINVEST Corporate City</name>
      <address>
        <city>Alabang, Muntinlupa City</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the East Ramon Magsaysay Medical Center, 64 Aurora Boulevard</name>
      <address>
        <city>Barangay Dona Imelda Quezon City</city>
        <zip>1113</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>De La Salle Health Sciences Institute</name>
      <address>
        <city>Dasmarinas Cavite</city>
        <zip>4115</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Chiles General Hospital, 667 Gastambide St. Sampaloc</name>
      <address>
        <city>Manila</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine Children's Medical Center, Quezon Avenue corner Agham Road</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Philippines</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2010</study_first_submitted>
  <study_first_submitted_qc>September 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <results_first_submitted>December 10, 2013</results_first_submitted>
  <results_first_submitted_qc>February 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2014</results_first_posted>
  <disposition_first_submitted>December 13, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>December 13, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 22, 2011</disposition_first_posted>
  <last_update_submitted>February 7, 2014</last_update_submitted>
  <last_update_submitted_qc>February 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>seasonal influenza, vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in 13 centers across 4 countries: Mexico, Colombia, Panama and Philippines.</recruitment_details>
      <pre_assignment_details>Due to GCP non-compliance at the Mexico site, data of 312 subjects (3-8 year olds) enrolled from this site were excluded from the final immunogenicity and safety analysis. The population was analyzed in the enrolled set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TIV (3-8 Years Old)</title>
          <description>The group consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). The non-naive subjects received one dose and naive subjects received two doses of investigational TIV.</description>
        </group>
        <group group_id="P2">
          <title>Control (4-8 Years)</title>
          <description>The group consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). The non-naive subjects received one dose and naive subjects received two doses of US licensed control vaccine- TIVf.</description>
        </group>
        <group group_id="P3">
          <title>Control (3 to &lt; 4 Years)</title>
          <description>The group consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination.The non-naive subjects received one dose and naive subjects received two doses of US licensed control vaccine- comparator TIV.</description>
        </group>
        <group group_id="P4">
          <title>TIV (9-17 Years)</title>
          <description>All subjects in this group were non-naive and received one dose of investigational TIV.</description>
        </group>
        <group group_id="P5">
          <title>Control (9-17 Years)</title>
          <description>All subjects in this group were non-naive and received one dose of US licensed control vaccine TIVf.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1042"/>
                <participants group_id="P2" count="485"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="817"/>
                <participants group_id="P5" count="412"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1016"/>
                <participants group_id="P2" count="467"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="807"/>
                <participants group_id="P5" count="407"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demography reported for all enrolled set except for 312 subjects (3-8 year olds) who were enrolled in the Mexico site.</population>
      <group_list>
        <group group_id="B1">
          <title>TIV (3-8 Years)</title>
          <description>The group consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). The non-naive subjects received one dose and naive subjects received two doses of investigational TIV.</description>
        </group>
        <group group_id="B2">
          <title>Control (3-8 Years)</title>
          <description>The group [control (4-8 years) + control (3 to&lt;4 years)] consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). Subjects (4-&lt;9 years) received TIVf and subjects (3-&lt;4 years) received comparator TIV. The non-naive subjects received one dose and naive subjects received two doses of vaccine.</description>
        </group>
        <group group_id="B3">
          <title>TIV (9-17 Years)</title>
          <description>All subjects received one dose of investigational TIV.</description>
        </group>
        <group group_id="B4">
          <title>Control (9-17 Years)</title>
          <description>All subjects received one dose of control TIV (eTIV_f).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1042"/>
            <count group_id="B2" value="533"/>
            <count group_id="B3" value="817"/>
            <count group_id="B4" value="412"/>
            <count group_id="B5" value="2804"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="1.6"/>
                    <measurement group_id="B2" value="5.6" spread="1.6"/>
                    <measurement group_id="B3" value="12.4" spread="2.4"/>
                    <measurement group_id="B4" value="12.3" spread="2.3"/>
                    <measurement group_id="B5" value="8.6" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="517"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="398"/>
                    <measurement group_id="B4" value="215"/>
                    <measurement group_id="B5" value="1399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="525"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="419"/>
                    <measurement group_id="B4" value="197"/>
                    <measurement group_id="B5" value="1405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Antibody Responses of Investigational TIV to Control Vaccine in Terms of the Percentage of Subjects Achieving Seroconversion</title>
        <description>The non-inferiority of the antibody responses of investigational TIV compared to control TIV assessed in terms of the percentage of subjects achieving seroconversion, against the three homologous vaccine strains,in children 3 to 8 years of age, at 21 days after last vaccination.
Seroconversion was defined as a pre-vaccination haemagglutinin inhibition (HI) titer &lt;1:10 and post-vaccination HI titer ≥1:40 or as a pre-vaccination HI titer ≥1:10 and at minimum four-fold rise in post-vaccination antibody titer</description>
        <time_frame>Day 22 for non-naive/Day 50 for naive subjects</time_frame>
        <population>Analysis was done on per protocol population i.e-all subjects who correctly received study vaccinations,provided evaluable serum samples at the relevant time points, and had no major protocol violation as defined prior to unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (3-8 Years)</title>
            <description>The group consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). The non-naive subjects received one dose and naive subjects received two doses of investigational TIV.</description>
          </group>
          <group group_id="O2">
            <title>Control (3-8 Years)</title>
            <description>The group [control (4-8 years) + control (3 to&lt;4 years)] consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). Subjects (4-&lt;9 years) received TIVf and subjects (3-&lt;4 years) received comparator TIV. The non-naive subjects received one dose and naive subjects received two doses of control vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of Investigational TIV to Control Vaccine in Terms of the Percentage of Subjects Achieving Seroconversion</title>
          <description>The non-inferiority of the antibody responses of investigational TIV compared to control TIV assessed in terms of the percentage of subjects achieving seroconversion, against the three homologous vaccine strains,in children 3 to 8 years of age, at 21 days after last vaccination.
Seroconversion was defined as a pre-vaccination haemagglutinin inhibition (HI) titer &lt;1:10 and post-vaccination HI titer ≥1:40 or as a pre-vaccination HI titer ≥1:10 and at minimum four-fold rise in post-vaccination antibody titer</description>
          <population>Analysis was done on per protocol population i.e-all subjects who correctly received study vaccinations,provided evaluable serum samples at the relevant time points, and had no major protocol violation as defined prior to unblinding.</population>
          <units>Percentages</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="918"/>
                <count group_id="O2" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain (N=916,467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="93" upper_limit="96"/>
                    <measurement group_id="O2" value="94" lower_limit="91" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain (N=917,468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="75" upper_limit="80"/>
                    <measurement group_id="O2" value="87" lower_limit="84" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="84" upper_limit="89"/>
                    <measurement group_id="O2" value="85" lower_limit="82" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of investigational TIV to control TIV against A/H1N1 influenza strain</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The investigational TIV was to be considered non-inferior to the control TIV if for all three strains the upper bound of the two-sided 95% CI on the difference between the seroconversion rates (Seroconversion control – Seroconversion investigational) at 21 days after last vaccination does not exceed 10 percentage points.</non_inferiority_desc>
            <param_type>Vaccine group difference (%)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of investigational TIV to control TIV against A/H3N2 influenza strain</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The investigational TIV was to be considered non-inferior to the control TIV if, for all three strains, the upper bound of the two-sided 95% CI on the difference between the seroconversion rates (Seroconversion control - Seroconversion investigational), at 21 days after last vaccination, does not exceed 10 percentage points</non_inferiority_desc>
            <param_type>Vaccine group difference (%)</param_type>
            <param_value>10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6</ci_lower_limit>
            <ci_upper_limit>14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of investigational TIV to the control TIV against B influenza strain</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The investigational TIV was to be considered non-inferior to the control TIV if, for all three strains, the upper bound of the two-sided 95% CI on the difference between the seroconversion rates (Seroconversion control - Seroconversion investigational), at 21 days after last vaccination, does not exceed 10 percentage points</non_inferiority_desc>
            <param_type>Vaccine group difference (%)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Achieving HI Titers ≥40 Following Vaccination With Investigational TIV or Control Vaccine.</title>
        <description>The percentages of 3 to 8 year old subjects achieving HI titers ≥40 after receiving either one or two doses of investigational TIV or control vaccine, 21 days after last vaccination, are reported.
This criterion according to the US (CBER)guideline is met if the lower bound of the two sided 95%CI for percentage of subjects achieving HI titers ≥40, is ≥70%.</description>
        <time_frame>Day 22 for non-naive/Day 50 for naive subjects</time_frame>
        <population>Analysis was performed on per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (3-8 Years)</title>
            <description>The group consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). The non-naive subjects received one dose and naive subjects received two doses of investigational TIV.</description>
          </group>
          <group group_id="O2">
            <title>Control (3-8 Years)</title>
            <description>The group [control (4-8 years) + control (3 to&lt;4 years)] consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). Subjects (4-&lt;9 years) received TIVf and subjects (3-&lt;4 years) received comparator TIV. The non-naive subjects received one dose and naive subjects received two doses of control vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Achieving HI Titers ≥40 Following Vaccination With Investigational TIV or Control Vaccine.</title>
          <description>The percentages of 3 to 8 year old subjects achieving HI titers ≥40 after receiving either one or two doses of investigational TIV or control vaccine, 21 days after last vaccination, are reported.
This criterion according to the US (CBER)guideline is met if the lower bound of the two sided 95%CI for percentage of subjects achieving HI titers ≥40, is ≥70%.</description>
          <population>Analysis was performed on per protocol population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="918"/>
                <count group_id="O2" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (H1N1strain, N=917,467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="46" upper_limit="53"/>
                    <measurement group_id="O2" value="48" lower_limit="44" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 or Day 50 (H1N1strain; N=917,468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="95" upper_limit="98"/>
                    <measurement group_id="O2" value="95" lower_limit="93" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (H3N2 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="81" upper_limit="86"/>
                    <measurement group_id="O2" value="85" lower_limit="82" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 or Day 50 (H3N2 strain; N=917,468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (B strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="21" upper_limit="26"/>
                    <measurement group_id="O2" value="26" lower_limit="22" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 or Day 50 (B strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="93" upper_limit="96"/>
                    <measurement group_id="O2" value="92" lower_limit="90" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Antibody Responses of Investigational TIV to Control Vaccine in Terms of Post Vaccination Geometric Mean Titers (GMTs)</title>
        <description>The non-inferiority of the antibody responses of investigational TIV compared to control vaccine assessed in terms of post vaccination GMTs, at 21 days after last vaccination against the three homologous vaccine strains in 3 to 8 year old children.</description>
        <time_frame>Day 22 for non-naive/Day 50 for naive subjects</time_frame>
        <population>Analysis was performed on the per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (3-8 Years)</title>
            <description>The group consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). The non-naive subjects received one dose and naive subjects received two doses of investigational TIV.</description>
          </group>
          <group group_id="O2">
            <title>Control (3-8 Years)</title>
            <description>The group [control (4-8 years) + control (3 to&lt;4 years)] consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). Subjects (4-&lt;9 years) received TIVf and subjects (3-&lt;4 years) received comparator TIV. The non-naive subjects received one dose and naive subjects received two doses of control vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Antibody Responses of Investigational TIV to Control Vaccine in Terms of Post Vaccination Geometric Mean Titers (GMTs)</title>
          <description>The non-inferiority of the antibody responses of investigational TIV compared to control vaccine assessed in terms of post vaccination GMTs, at 21 days after last vaccination against the three homologous vaccine strains in 3 to 8 year old children.</description>
          <population>Analysis was performed on the per protocol population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="918"/>
                <count group_id="O2" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (H1N1 strain, N=917,467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="22" upper_limit="31"/>
                    <measurement group_id="O2" value="28" lower_limit="25" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 or Day 50 (H1N1 strain,N=917,468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1157" lower_limit="1052" upper_limit="1272"/>
                    <measurement group_id="O2" value="1501" lower_limit="1283" upper_limit="1756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (H3N2 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142" lower_limit="127" upper_limit="158"/>
                    <measurement group_id="O2" value="150" lower_limit="129" upper_limit="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 or Day 50 (H3N2 strain, N=917,468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1385" lower_limit="1300" upper_limit="1475"/>
                    <measurement group_id="O2" value="2032" lower_limit="1843" upper_limit="2240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (B strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="11" upper_limit="13"/>
                    <measurement group_id="O2" value="13" lower_limit="12" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 or Day 50 (B strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208" lower_limit="193" upper_limit="224"/>
                    <measurement group_id="O2" value="195" lower_limit="174" upper_limit="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of investigational TIV to licensed control TIV against A/H1N1 influenza strain</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The investigational TIV was to be considered non-inferior to the control TIV, if for all three strains, the upper bound of the two-sided 95% CI on the ratio of the GMTs (GMTcontrol/GMTinvestigational) at 21 days after last vaccination does not exceed 1.5</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of investigational TIV to licensed control TIV against A/H3N2 influenza strain</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The investigational TIV was to be considered non-inferior to the control TIV, if for all three strains, the upper bound of the two-sided 95% CI on the ratio of the GMTs (GMTcontrol/GMTinvestigational) at 21 days after last vaccination does not exceed 1.5</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.34</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of investigational TIV to licensed control TIV against B influenza strain</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The investigational TIV was to be considered non-inferior to the control TIV, if for all three strains, the upper bound of the two-sided 95% CI on the ratio of the GMTs (GMTcontrol/GMTinvestigational) at 21 days after last vaccination does not exceed 1.5</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Seroconversion in Antibody Titers Following Vaccination With Investigational TIV or Control Vaccine</title>
        <description>The percentages of 3 to 8 years-old subjects achieving seroconversion in HI antibody titers after receiving either one or two doses of investigational TIV or control vaccine, at 21 days after last vaccination, are reported.
This criterion, according to the US (CBER) guideline, is met if the lower limit of 95% CI of percentage of subjects achieving seroconversion or significant increase at day 22 and day 50 (21 days after last vaccination) is ≥40.</description>
        <time_frame>Day 22 for non-naive/Day 50 for naive</time_frame>
        <population>Analysis was performed on the per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (3-8 Years)</title>
            <description>The group consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). The non-naive subjects received one dose and naive subjects received two doses of investigational TIV.</description>
          </group>
          <group group_id="O2">
            <title>Control (3-8 Years)</title>
            <description>The group [control (4-8 years) + control (3 to&lt;4 years)] consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). Subjects (4-&lt;9 years) received TIVf and subjects (3-&lt;4 years) received comparator TIV. The non-naive subjects received one dose and naive subjects received two doses of control vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Seroconversion in Antibody Titers Following Vaccination With Investigational TIV or Control Vaccine</title>
          <description>The percentages of 3 to 8 years-old subjects achieving seroconversion in HI antibody titers after receiving either one or two doses of investigational TIV or control vaccine, at 21 days after last vaccination, are reported.
This criterion, according to the US (CBER) guideline, is met if the lower limit of 95% CI of percentage of subjects achieving seroconversion or significant increase at day 22 and day 50 (21 days after last vaccination) is ≥40.</description>
          <population>Analysis was performed on the per protocol population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="918"/>
                <count group_id="O2" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 strain (N= 916,467)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="93" upper_limit="96"/>
                    <measurement group_id="O2" value="94" lower_limit="91" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 strain ( N= 917,468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="75" upper_limit="80"/>
                    <measurement group_id="O2" value="87" lower_limit="84" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="84" upper_limit="89"/>
                    <measurement group_id="O2" value="85" lower_limit="82" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Vaccine-naive Children Achieving HI Titers ≥40 After Receiving Two Doses of Investigational TIV or Control Vaccine.</title>
        <description>The percentage of 3 to 8 years-old vaccine-naive subjects achieving HI titers ≥40, after receiving two doses of investigational TIV or control vaccine. The time frame of evaluation was 28 days after first (Day 29) and 21 days after second vaccine dose (Day 50).
This criterion according to the US (CBER) guideline is met if the lower bound of the two sided 95%CI for percentage of subjects achieving HI titers ≥40 is ≥70%, for each vaccine strain.</description>
        <time_frame>Day 1, Day 29, and Day 50</time_frame>
        <population>Analysis was done on the per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (3-8 Years)</title>
            <description>The group consisted of naive subjects (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) who received two doses of investigational TIV.</description>
          </group>
          <group group_id="O2">
            <title>Control (3-8 Years)</title>
            <description>The group [control (4-8 years) + control (3 to &lt;4 years)] consisted of naive subjects (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) who received two doses of control vaccine. Subjects (4-&lt;9 years) received TIVf and subjects (3-&lt;4 years) received two doses of comparator TIV.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Vaccine-naive Children Achieving HI Titers ≥40 After Receiving Two Doses of Investigational TIV or Control Vaccine.</title>
          <description>The percentage of 3 to 8 years-old vaccine-naive subjects achieving HI titers ≥40, after receiving two doses of investigational TIV or control vaccine. The time frame of evaluation was 28 days after first (Day 29) and 21 days after second vaccine dose (Day 50).
This criterion according to the US (CBER) guideline is met if the lower bound of the two sided 95%CI for percentage of subjects achieving HI titers ≥40 is ≥70%, for each vaccine strain.</description>
          <population>Analysis was done on the per protocol population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="820"/>
                <count group_id="O2" value="413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (H1N1 strain, N=819,412)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="46" upper_limit="53"/>
                    <measurement group_id="O2" value="48" lower_limit="43" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (H1N1 strain, N=819,413)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="80" upper_limit="86"/>
                    <measurement group_id="O2" value="82" lower_limit="78" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (H1N1 strain, N= 819,413)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (H3N2 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="85" upper_limit="90"/>
                    <measurement group_id="O2" value="90" lower_limit="87" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (H3N2 strain, N= 819, 413)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (H3N2 strain,N= 819, 413)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (B strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="22" upper_limit="28"/>
                    <measurement group_id="O2" value="26" lower_limit="22" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (B strain, N= 820,412)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="79" upper_limit="84"/>
                    <measurement group_id="O2" value="81" lower_limit="77" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (B strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O2" value="94" lower_limit="92" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Vaccine-naive Children Achieving Seroconversion in Antibody Titers, After Receiving Two Doses of Investigational TIV or Control Vaccine</title>
        <description>The percentages of 3 to 8 years-old vaccine naive children achieving seroconversion or significant increase in HI antibody titers after receiving two doses of investigational TIV or control vaccine, are reported. The time frame of evaluation was 28 days after first (Day 29) and 21 days after the second dose (Day 50).
This criterion, according to the US (CBER) guideline, is met if the lower limit of 95% CI of percentage of subjects achieving seroconversion or significant increase at day 29 and day 50 is ≥40, for each vaccine strain.</description>
        <time_frame>Day 29 and Day 50</time_frame>
        <population>Analysis was done on the per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (3-8 Years)</title>
            <description>The group consisted of naive subjects (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) who received two doses of investigational TIV.</description>
          </group>
          <group group_id="O2">
            <title>Control (3-8 Years)</title>
            <description>The group [control (4-8 years) + control (3 to &lt;4 years)] consisted of naive subjects (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) who received two doses of control vaccine. Subjects (4-&lt;9 years) received TIVf and subjects (3-&lt;4 years) received two doses of comparator TIV.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Vaccine-naive Children Achieving Seroconversion in Antibody Titers, After Receiving Two Doses of Investigational TIV or Control Vaccine</title>
          <description>The percentages of 3 to 8 years-old vaccine naive children achieving seroconversion or significant increase in HI antibody titers after receiving two doses of investigational TIV or control vaccine, are reported. The time frame of evaluation was 28 days after first (Day 29) and 21 days after the second dose (Day 50).
This criterion, according to the US (CBER) guideline, is met if the lower limit of 95% CI of percentage of subjects achieving seroconversion or significant increase at day 29 and day 50 is ≥40, for each vaccine strain.</description>
          <population>Analysis was done on the per protocol population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="820"/>
                <count group_id="O2" value="413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29 (H1N1 strain, N= 818,412)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="79" upper_limit="84"/>
                    <measurement group_id="O2" value="81" lower_limit="77" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (H1N1 strain, N= 818,412)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O2" value="96" lower_limit="94" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (H3N2 strain, N= 819,413)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="71" upper_limit="77"/>
                    <measurement group_id="O2" value="87" lower_limit="83" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (H3N2 strain, N= 819,413)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="75" upper_limit="80"/>
                    <measurement group_id="O2" value="87" lower_limit="84" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (B strain, N= 820,412)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="71" upper_limit="77"/>
                    <measurement group_id="O2" value="73" lower_limit="68" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (B strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="87" upper_limit="91"/>
                    <measurement group_id="O2" value="88" lower_limit="85" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Adverse Events After Vaccination With Investigational TIV and Control Vaccine</title>
        <description>The number of 3-17 year old children with solicited local and systemic adverse events and other adverse events, after receiving either one or two doses of investigational TIV as compared to control vaccine are reported.</description>
        <time_frame>Day 1 to 7 after vaccination</time_frame>
        <population>Analysis was done on the safety set population i.e all subjects who received at least one study vaccine and provided post vaccination safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (3-8 Years)</title>
            <description>The group consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). The non-naive subjects received one dose and naive subjects received two doses of investigational TIV.</description>
          </group>
          <group group_id="O2">
            <title>Control (3-8 Years)</title>
            <description>The group [control (4-8 years) + control (3 to&lt;4 years)] consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). Subjects (4-&lt;9 years) received TIVf and subjects (3-&lt;4 years) received comparator TIV. The non-naive subjects received one dose and naive subjects received two doses of control vaccine.</description>
          </group>
          <group group_id="O3">
            <title>TIV (9-17 Years)</title>
            <description>All subjects received one dose of investigational TIV.</description>
          </group>
          <group group_id="O4">
            <title>Control (9-17 Years)</title>
            <description>All subjects received one dose of control vaccine(TIVf).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Adverse Events After Vaccination With Investigational TIV and Control Vaccine</title>
          <description>The number of 3-17 year old children with solicited local and systemic adverse events and other adverse events, after receiving either one or two doses of investigational TIV as compared to control vaccine are reported.</description>
          <population>Analysis was done on the safety set population i.e all subjects who received at least one study vaccine and provided post vaccination safety data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1037"/>
                <count group_id="O2" value="531"/>
                <count group_id="O3" value="817"/>
                <count group_id="O4" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="364"/>
                    <measurement group_id="O2" value="216"/>
                    <measurement group_id="O3" value="270"/>
                    <measurement group_id="O4" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363"/>
                    <measurement group_id="O2" value="215"/>
                    <measurement group_id="O3" value="268"/>
                    <measurement group_id="O4" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                    <measurement group_id="O2" value="161"/>
                    <measurement group_id="O3" value="193"/>
                    <measurement group_id="O4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=1037,531,817,411)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyretic med.used(N=1032,531,816,412)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed at home due to reaction(N=1019,524,809,411)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events After Vaccination With Investigational TIV and Control Vaccine</title>
        <description>The number of 3-17 year old children reporting any unsolicited adverse event and any serious adverse event (SAE) after receiving either one or two doses of investigational TIV and control vaccine are reported.</description>
        <time_frame>Day 1 to 180 (non-naive )/Day 1 to 209 (naive)</time_frame>
        <population>Analysis was done on the safety set population.</population>
        <group_list>
          <group group_id="O1">
            <title>TIV (3-8 Years)</title>
            <description>The group consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). The non-naive subjects received one dose and naive subjects received two doses of investigational TIV.</description>
          </group>
          <group group_id="O2">
            <title>Control (3-8 Years)</title>
            <description>The group [control (4-8 years) + control (3 to&lt;4 years)] consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). Subjects (4-&lt;9 years) received TIVf and subjects (3-&lt;4 years) received comparator TIV. The non-naive subjects received one dose and naive subjects received two doses of control vaccine.</description>
          </group>
          <group group_id="O3">
            <title>TIV (9-17 Years)</title>
            <description>All subjects received one dose of investigational TIV.</description>
          </group>
          <group group_id="O4">
            <title>Control (9-17 Years)</title>
            <description>All subjects received one dose of control vaccine (TIVf).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events After Vaccination With Investigational TIV and Control Vaccine</title>
          <description>The number of 3-17 year old children reporting any unsolicited adverse event and any serious adverse event (SAE) after receiving either one or two doses of investigational TIV and control vaccine are reported.</description>
          <population>Analysis was done on the safety set population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1039"/>
                <count group_id="O2" value="531"/>
                <count group_id="O3" value="817"/>
                <count group_id="O4" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395"/>
                    <measurement group_id="O2" value="194"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited adverse events collected from Day 1-7 after each vaccination. Serious adverse events and other unsolicited adverse events were collected from Day 1-180 for non-naive and Day 1-209 for vaccine-naive subjects.</time_frame>
      <desc>The population analyzed here is the safety set.</desc>
      <group_list>
        <group group_id="E1">
          <title>TIV (3-8 Years)</title>
          <description>The group consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). The non-naive subjects received one dose and naive subjects received two doses of investigational TIV.</description>
        </group>
        <group group_id="E2">
          <title>Control (3-8 Years)</title>
          <description>The group [control (4-8 years) + control (3 to&lt;4 years)] consisted of naive (who have never received influenza vaccination or had received only one influenza vaccine dose in the same season) and non-naive subjects (who had a record of previous influenza vaccination). Subjects (4-&lt;9 years) received TIVf and subjects (3-&lt;4 years) received comparator TIV. The non-naive subjects received one dose and naive subjects received two doses of control vaccine.</description>
        </group>
        <group group_id="E3">
          <title>TIV (9-17 Years)</title>
          <description>All subjects received one dose of investigational TIV.</description>
        </group>
        <group group_id="E4">
          <title>Control (9-17 Years)</title>
          <description>All subjects received one dose of control vaccine (TIV_f).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="412"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Ascariasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Cholera</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="412"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="657" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="342" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="385" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="196" subjects_at_risk="412"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="363" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="215" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="268" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="146" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>malaise</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="412"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharingitis</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="412"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="412"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="412"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hyperhidrosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1039"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="531"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="817"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="412"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to GCP non-compliance at the Mexico site, data of 312 subjects (3-8 year olds) enrolled from this site were excluded from the final immunogenicity and safety analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

